Chemiluminescence Immunoassay Market Size

Chemiluminescence Immunoassay Market Size

Chemiluminescence Immunoassay Market size was valued at around USD 9.8 billion in 2023 and is estimated to grow at 7.3% CAGR from 2024 to 2032. Chemiluminescence immunoassay (CLIA) is a laboratory technique used to detect specific molecules (such as proteins, hormones, drugs, or antibodies) in biological samples. It combines the principles of chemiluminescence, which is the emission of light resulting from a chemical reaction, with the specificity of immunoassay techniques.

To get key market trends

  Download Free Sample

The escalating prevalence of chronic conditions such as cardiovascular diseases, diabetes, cancer, and infectious diseases such as COVID-19 has underscored the urgent need for accurate diagnostic solutions. According to the World Health Organization (WHO), Noncommunicable Diseases (NCDs) claim 41 million lives annually, amounting to approximately 74% of global fatalities, with 17 million deaths occurring before age 70. Cardiovascular diseases top the list with 17.9 million fatalities, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million, including deaths from diabetes-related kidney disease). Therefore, as the prevalence of these chronic conditions increases, chemiluminescence immunoassay (CLIA) emerges as a pivotal technology, offering remarkable sensitivity and specificity for the diagnosis and monitoring of various medical conditions.
 

Furthermore, CLIA has found expanding applications beyond clinical diagnostics, particularly in drug development and clinical research. Pharmaceutical companies use CLIA for biomarker analysis, pharmacokinetic studies, and therapeutic drug monitoring. Its ability to quantify specific analytes with high precision and sensitivity makes CLIA an indispensable tool in these fields.